RepliCel Life Sciences Inc. Share Price
Equities
REPCF
CA76027P4006
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0428 USD | +4.99% | -.--% | -4.89% |
04-18 | RepliCel Life Sciences Inc. Announces Secured Loan Agreement | CI |
2023 | RepliCel Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
Sales 2021 | 0.35 28.32 | Sales 2022 | 0.35 28.32 | Capitalization | 2.98M 238M |
---|---|---|---|---|---|
Net income 2021 | -4M -320M | Net income 2022 | - 0 | EV / Sales 2021 | 26,101,234 x |
Net Debt 2021 | 407K 32.6M | Net Debt 2022 | 300K 24.01M | EV / Sales 2022 | 9,264,363 x |
P/E ratio 2021 |
-1.83
x | P/E ratio 2022 |
-3.54
x | Employees | 1 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 39.48% |
1 day | +4.99% | ||
3 months | -11.39% | ||
6 months | -33.44% | ||
Current year | -4.89% |
Managers | Title | Age | Since |
---|---|---|---|
Andrew Schutte
CEO | Chief Executive Officer | 35 | 13/12/18 |
Rolf Hoffmann
FOU | Founder | 63 | - |
Kevin McElwee
FOU | Founder | 54 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hall
CHM | Chairman | 71 | 21/12/10 |
Peter Lewis
BRD | Director/Board Member | 69 | 26/05/11 |
Rolf Hoffmann
FOU | Founder | 63 | - |
1st Jan change | Capi. | |
---|---|---|
-4.89% | 2.78M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- REPCF Stock